MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
equity securities
$108,101K
Proceeds from exercise of
stock options
$14K
Maturities of marketable
securities
$29,000K
Net cash provided by
financing activities
$108,115K
Net cash provided by
(used in) investing...
$29,000K
Net increase in
cash, cash...
$92,501K
Canceled cashflow
$44,614K
Accounts payable
$2,925K
Stock-based compensation
expense
$1,979K
Prepaid expenses and
other current assets
-$578K
Depreciation expense
$64K
Other assets
-$19K
Net cash used in
operating activities
-$44,614K
Canceled cashflow
$5,565K
Other income, net
$1,504K
Net loss
-$29,613K
Accrued expenses
-$20,401K
Canceled cashflow
$1,504K
Lease expense
-$85K
Amortization of premium on
marketable securities
-$80K
Operating expenses
$31,117K
Back
Back
Cash Flow
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)
source: myfinsight.com